according 10-QSB the O/S is 499,999,995 as of 2005-08-25 R/S 1/400 and O/S is 1,250,000 as of 2005-09-20 (pinksheets info)
I'm going to call TA on Tuesday for actual numbers but looks like they are diluted to 150m - 250m+ already...
Latest acquisition should be finalized soon and few day runs are just MMs test-drive (NANN was .05 in the mid of March!)
look how MMs play with it: August 29: open 0.0016 high .0024 low .0015 close .0022 August 30: open 0.0024 high .005 low .0024 close .0026 August 31: open 0.0025 high .0042 low .0025 close .0026 September 1: open 0.0026 high .0026 low .0021 close .0022
PRs: ********************************** Nannaco Inc. Announces That Its Acquisition Target, CPRS, Will Commence Remote Treatment Planning at Maryview Hospital in Virginia
GIG HARBOR, Wash., Aug 11, 2006 (PRIMEZONE via COMTEX) -- Nannaco, Inc. ("Nannaco") (Pink Sheets:NANN) announced that it will begin remote treatment planning at Maryview Hospital, located in Virginia. It is expected that the hospital will conduct 4-5 remote treatment plans for cancer radiation patients in the next month, which should grow to 10 treatment plans per month. It is projected that this will increase CPRS revenues by approximately $150,000 over the next 12 months. CPRS is a 12-year-old-firm that provides specialized, internet-based treatment plans and medical physics consulting services for radiation centers. Nannaco's acquisition of CPRS will provide the foundation for the entity to achieve significant revenue growth from both (i) internal expansion of CPRS's existing business, and (ii) from its plan for future acquisitions in the highly fragmented radiation and cancer industries. CPRS achieved revenues of approximately $1,700,000.00 for the year ended 2005, with EBITDA of approximately $100,000.00. Management believes that the merger will provide CPRS with greater access to capital, with which it intends to commence enhanced sales and marketing efforts.
About NANNACO, INC.
Nannaco, Inc. previously provided surface cleaning, surface protection, surface restoration and other services to commercial and industrial businesses, as well as to owners of historical buildings. The company has moved to a new line of business as a consultant and advisor to customers, and is seeking to improve its financial position through the acquisition of, or merger with, companies capable of providing the best value to its shareholders.
NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) the company's limited operating history; (2) the company's ability to pay down existing debt; (3) the company's ability to retain the professional advisors necessary to guide us through our corporate restructuring; (4) the company's ability to secure necessary financing; (5) potential litigation by shareholders and/or former or current advisors against the company; (6) the company's success in securing third-party commitments, production agreements and/or licensing contracts; (7) the company's ability to comply with federal, state and local government regulations and/or unforeseen changes in federal or and government regulations; and (8) the risks inherent in the investigation and consummation of the acquisition of a new business opportunity or other factors over which we have little or no control.
For further information, please contact Steve Careaga at (253) 853-3632, or send correspondence to 4916 Point Fosdick Dr., Suite 102, Gig Harbor, WA 98335.
CONTACT: Nannaco, Inc. Steve Careaga (253) 853-3632
(C) 2006 PRIMEZONE, All rights reserved.
***************************************** Nannaco Inc. Announces the Receipt of Acquisition Funding and Expects to Acquire Internet Based Radiation Oncology Treatment Planning Firm Within the Week
GIG HARBOR, Wash., Aug 3, 2006 (PRIMEZONE via COMTEX) -- Nannaco, Inc. ("Nannaco") (Pink Sheets:NANN) announced the receipt of acquisition funding from TTTK Capital Partners, LLC which will allow the company to close on the merger with GAK Acquisition, Inc. thereby acquiring Comprehensive Physics & Rehabilitation Services ("CPRS"). The merger is expected to close within the next few days. CPRS is a 12 year old firm that provides specialized internet based treatment plans and medical physics consulting services for radiation centers. Nannaco's acquisition of CPRS will provide the foundation for the entity to achieve significant revenue growth from both (i) internal expansion of CPRS's existing business, and (ii) from its plan for future acquisitions in the highly fragmented radiation and cancer industries. CPRS achieved revenues of approximately $1,700,000.00 for the year ended 2005 with EBITDA of approximately $ 100,000.00. Management believes that the merger will provide CPRS with greater access to capital with which it intends to commence enhanced sales and marketing efforts.
About Nannaco, Inc.
Nannaco, Inc. previously provided surface cleaning, surface protection, surface restoration and other services to commercial and industrial businesses, as well as to owners of historical buildings. The company has moved to a new line of business as a consultant and advisor to customers and is seeking to improve its financial position through the acquisition of, or merger with, companies capable of providing the best value to its shareholders.
NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things: (1) the company's limited operating history; (2) the company's ability to pay down existing debt; (3) the company's ability to retain the professional advisors necessary to guide us through our corporate restructuring; (4) the company's ability to secure necessary financing; (5) potential litigation by shareholders and/or former or current advisors against the company; (6) the company's success in securing third-party commitments, production agreements and/or licensing contracts; (7) the company's ability to comply with federal, state and local government regulations and/or unforeseen changes in federal or and government regulations; and (8) the risks inherent in the investigation and consummation of the acquisition of a new business opportunity or other factors over which we have little or no control. For further information, please contact Steve Careaga at (253) 853-3632, or send correspondence to 4916 Point Fosdick Dr., Suite 102, Gig Harbor, WA 98335.
CONTACT: Nannaco, Inc. Steve Careaga (253) 853-3632
(C) 2006 PRIMEZONE, All rights reserved. ************************************************
old one: Nannaco, Inc. Announces Execution of Definitive Merger Agreement with Premier Developer and Manufacturer of Nutraceuticals GIG HARBOR, Wash., Aug. 9, 2005 (PRIMEZONE) -- Nannaco, Inc. (OTCBB:NNNC) ("Nannaco") announced that on July 21, 2005 it entered into a Definitive Merger Agreement with Amenni, Inc. ("Amenni") located in Ft. Lauderdale, Florida.
Amenni is a premier developer and manufacturer of Nutraceuticals. Amenni develops and manufactures joint-care nutraceutical products for dogs and horses. In addition to Ft. Lauderdale, Amenni has facilities located in London (United Kingdom), Dubai (United Arab Emirates) and Zurich (Switzerland).
Amenni has initially distributed these product lines through a distribution agreement with an internationally recognized pharmaceutical firm. Revenues in the first 12 months from this agreement exceeded $1 million, and the first product was launched in 10 countries. Amenni anticipates a roll-out to an additional 15-20 countries, including the U.S., within the next 12 months.
Amenni has also initiated the launch of its highly innovative Sports Patch into the U.S. OTC market. Its primary active ingredients have been developed in conjunction with its highly successful research into Veterinary Science.
The Sports Patch is targeting the fast-growing Sports Healthcare market and has shown significant benefits to aid the recovery from a sports injury. Joint and ligament injuries happen to all athletes. The Amenni Sports Patch applied immediately after injury helps with quicker recovery times. Currently, there are no direct competitors in the marketplace.
Amenni has already begun production of patches for a substantial U.S. client.
Amenni is developing additional products for distribution by this and other distribution partners. Furthermore, Amenni continues to develop nutraceutical products aimed at the human (as well as animal) marketplace. For 2004, Amenni has indicated that its combined revenues exceeded $3 million and anticipates strong growth in 2005.
On July 21, 2005, Nannaco entered into an agreement to merge a wholly owned subsidiary of Registrant with and into Amenni, and to rename Registrant "Amenni Inc." (the "reverse merger"). The agreement provides that all of the shares of common stock of Amenni, issued and outstanding at the time the merger becomes effective under applicable state law (the "Effective Time"), will be converted into common stock of Registrant such that the current holders of Amenni common stock will hold 97% of all shares of Registrant's common stock outstanding immediately after the closing of this merger transaction.
NOTE: Information contained in this press release, other than historical information, should be considered forward-looking in nature and is subject to various risks or uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or expected. Among the key factors that may have a direct bearing on the operating results, performance or financial condition are the company's ability to achieve and manage growth; the company's ability to attract and retain qualified personnel; the company's ability to secure necessary financing; potential litigation by shareholders and/or former or current advisors against the company; the company's success in securing third-party commitments, production agreements and/or licensing contracts; the company's ability to comply with federal, state and local government regulations and/or unforeseen changes in federal or and government regulation; and the company's ability to develop new services; and other factors discussed in Nannaco's filings with the Securities and Exchange Commission.
CONTACT: Nannaco, Inc. Steve Careaga 253-853-3632
or
Send correspondence to: 4916 Point Fosdick Dr., Suite 102 Gig Harbor, WA 98335
IP: Logged |
TO BECOME THE LEADING NATIONAL PROVIDER OF RADIATION THERAPY ONCOLOGY SERVICES IN CONCERT WITH OUR PHYSICIAN PARTNERS, FOCUSED ON QUALITY PATIENT CARE AND STATE-OF-THE-ART TECHNOLOGIES.
Growth Strategy
The Company believes that the national market for radiation oncology services offers substantial growth opportunities as the fragmented market consolidates and new treatment methods are introduced into care delivery settings. In order to capture the growth opportunities, OnCURE has developed the following strategic initiatives. Execute acquisitions to broaden geographic footprint within target states and capture economies of scale.
Management has extensive experience successfully executing acquisitions that have helped to propel the Company’s historical growth. These acquisitions have typically been focused on geographically proximate centers with existing referral streams and a need for capital and expertise required to purchase and implement the latest treatment technologies. The Company’s extensive experience growing center profitability drives down the effective multiples paid for its acquisitions through post-transaction revenue and EBITDA growth
Continue pursuit of organic growth opportunities to drive baseline revenue growth.
The Company estimates that increases in cancer incidence and diagnosis can provide up to 5% annual revenue growth. In addition to the baseline market growth, OnCURE has extensive experience in improving the efficiency of its centers as IMRT and other technologies are deployed. The Company’s centerlevel initiatives are anticipated to drive an additional 5-10% annual revenue growth over the next five years. In 2004-2006, OnCURE expanded its senior management team with the addition of Richard Zehner as CEO as well as other senior managers (see “Management”) to reinforce and expand organic growth opportunities. The Company is also currently undergoing branding efforts to leverage its reputation as a leader in providing radiation therapy services.
Invest in technology and service improvements to maintain high standards of physician service.
OnCURE’s operational model is focused on enabling the Company’s physician partners to optimize patient outcomes by providing the best available treatment options and technologies. Therefore, with each acquisition and new center developed, the Company develops a technology and service plan to ensure that the resources are available to the physician partner to generate significant and incremental value from the existing referral stream while improving levels of patient care.
Maintain and enhance high standard of patient care to improve same store sales.
OnCURE has a long history of maintaining a high level of patient service that has enabled the Company’s referral streams to improve over time. Management continues to work diligently to ensure that the level of patient care remains strong while constantly looking for innovative ways to improve upon each patient’s experience. Furthermore, management requires that each acquired facility maintains standards that are consistent with or exceed the Company’s existing level of outstanding patient care to ensure that the referral streams associated with these acquired facilities are maintained and enhanced.
posted
Hey Cactus, are you in the nvmg bottom buster? Busting right now!!
Native American Energy Group Orders NOBO List to Clarify Ownership and Address Potential Short Positions Tuesday October 17, 11:02 am ET
FOREST HILLS, N.Y.--(BUSINESS WIRE)--Native American Energy Group, Inc. (the "Company" or "NAEG") (OTC Pink Sheets: NVMG - News) announced that it has ordered the latest NOBO information for analysis and comparison in order to clarify all owners of its issued and outstanding shares and address potential short positions in NAEG's stock that management believes needs to be researched and examined to ensure integrity in the marketplace for its shares. ADVERTISEMENT
The NOBO list is a non-objecting beneficial owners list that offers the names and share positions of the clients of banks and brokers who hold their positions in street name. Company management elaborated that it will analyze current NOBO information to monitor shifts in shareholder positions, verify (non-objecting) beneficial owner and institutional positions, and collate NOBO provided data with that of other Company sources including the Company's transfer agent list.
After comparing the NOBO list to the current transfer agent list, the company will be able to determine if there is a share imbalance or a significant failure to deliver position in their stock. If the Company's research and examination does find an imbalance in regards to the reported short positions, the company will act to correct the problem.
"We will diligently review, examine and, in effect, audit our share numbers to give the Company a concise look at the specific ownership positions of NAEG's shares. The use of this information will increase the Company's visibility and emphasize our resolve to increase shareholder value through the fair and proper market valuation of our stock," commented, Director Richard Ross.
posted
Not too much talk about this move today. I must be missing something. I got in at the bottom ans man was it hard to fill at the ask.
IP: Logged |
posted
Sep 25, 2006 ONCURE MEDICAL CORP. ANNOUNCES THE APPOINTMENT OF DAVID S. CHERNOW TO THE BOARD OF DIRECTORS OF ONCURE HOLDINGS, INC.
Newport Beach, California - OnCURE Medical Corp. (“OnCURE”), a leading provider of outpatient radiation therapy services, today announced the appointment of David S. Chernow to the Board of Directors of its parent corporation, OnCURE Holdings, Inc. Mr. Chernow joins Dr. Shyam Paryani (Chairman), Jeffrey Goffman , James Nadauld, Robert Weltman and Richard Zehner on the Board of Directors of OnCURE Holdings, Inc.
Richard Zehner , OnCURE’s Chief Executive Officer, stated, “We are excited about Mr. Chernow joining the Board of Directors. David’s prior experience in the oncology sector will provide OnCURE with valuable insight with respect to growth and management as OnCURE continues to execute its strategic acquisition and development plans.”
David S. Chernow has held the position of global President and Chief Executive Officer of JA Worldwide™ (Junior Achievement) since January 2005. Beginning in July 2001, Mr. Chernow was appointed President and CEO of Junior Achievement Inc., responsible for leading the organization. Mr. Chernow was previously President of the Physician Services Group at US Oncology from 1990 to 2001, and was responsible for development and operations for a network of more than 850 physicians in 26 states, with 74 comprehensive cancer centers and 8,000 employees at the time of his departure in 2001. Mr. Chernow was co-founder of American Oncology Resources (AOR) in 1992, and served as Chief Development Officer of AOR prior to the merger in 1999 between AOR and another company which led to the formation of US Oncology. Mr. Chernow earned his J.D. at Pepperdine University and his undergraduate degree from UCLA.
About OnCURE
OnCURE owns, operates and manages 33 radiation centers and other mobile HDR & PET/CT units, all located in California and Florida. OnCURE's centers provide treatment areas and equipment for radiation therapy and diagnostic radiology, including IMRT, CT and PET. OnCURE provides capital, technology, and management expertise to its affiliated physician groups (approximately 55 doctors), including clinical management, billing and collection, data warehousing, accounting, compliance and other administrative services. OnCURE has approximately 350 employees. For more information, visit www.OnCURE.com.
About Genstar Capital, LLC.
Based in San Francisco , Genstar Capital (www.gencap.com) is a private equity investment firm that makes leveraged investments in quality middle-market companies. Genstar Capital works in partnership with management to transform its portfolio companies into industry-leading businesses. With more than $900 million of committed capital under management and significant experience investing in businesses, Genstar focuses on selected segments of the health care services, life sciences, business services, and industrial technology sectors.
posted
No trades today, hmmmm! It started yesterday around noon. Some bought yetsrday but because it was hard to buy at the ask I would think the MM's are looking for sellers at this time not buyers.
IP: Logged |
posted
watch this folks something is up. They brought this down to .0005 the other day to shake out some sellers but found there were some buyers looking to get in. I put a buy in * .009 and they would only give me 50,000 at that price and move up the bid to .0009 and raised the ask to .001 and they only gave me small orders of 15,000 25,000 10,000. They then raised the ask to .0011 and I stopped chasing it. Looking for another pullback.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
